ArticleThe Journal of infectious diseases2021
Global Experience With Rotavirus Vaccines.
Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Healthcare-Associated Gastroenteritis: Outbreak Report and Systematic Review of the Literature.Journal of the Pediatric Infectious Diseases Society · 2025Pooled it
- Trial
- Review
- Quantitative benefit-risk analysis for prophylactic vaccines in the context of FDAs benefit-risk framework.NPJ vaccines · 2026Review
- Hidden Circulation and Socio-Sanitary Vulnerability: Rotavirus A and Human Adenovirus Prevalence in Symptomatic and Asymptomatic Children in Central Brazil Post-COVID-19.Pathogens (Basel, Switzerland) · 2025Article
- Comparison of Clinical Profiles and Trends of Rotavirus Gastroenteritis in the Prevaccine and Postvaccine Periods Among Children Aged Under 5 Years in the Western States of Gujarat and Maharashtra, India.Indian journal of pediatrics · 2025Article
- Pentavalent rotavirus vaccine effectiveness among children in Shenzhen, China: A population-based test-negative design with directed acyclic graphs bias adjustment.Infectious medicine · 2025Article
- Rotavirus Vaccine Effectiveness Stratified By National-Level Characteristics: An Introduction to the 24-Country MNSSTER-V Project, 2007-2023.The Journal of infectious diseases · 2025Article
- Article
- Zinc as a treatment modality for acute infectious diarrhea in children.Clinical and experimental pediatrics · 2025Article
- Global trends, inequalities, and pathogen shifts in infectious diarrhea among children under five: a comprehensive analysis of the global burden of disease study 1990-2021.Frontiers in nutrition · 2025Article
- The 2Human vaccines & immunotherapeutics · 2024Article
- Health economic evaluation of 2-dose and 3-dose rotavirus vaccines in children below 5 years of age in Morocco.Human vaccines & immunotherapeutics · 2024Article
- Exploring the impact of rotavirus vaccination on antibiotic prescription and resistance: A comprehensive systematic review.World journal of virology · 2024Article
- Article
- Genotypic investigation of a rotavirus cluster at a quaternary-care pediatric hospital.Infection control and hospital epidemiology · 2023Article
- Article
- Phylogeography of Rotavirus G8P[8] Detected in Argentina: Evidence of Transpacific Dissemination.Viruses · 2022Article
- Biolayer Interferometry Analysis for a Higher Throughput Quantification of In-Process Samples of a Rotavirus Vaccine.Vaccines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rotavirus is a major cause of severe pediatric diarrhea worldwide. In 2006, 2 live, oral rotavirus vaccines, Rotarix and RotaTeq, were licensed for use in infants and were rapidly adopted in many high- and middle-income settings where efficacy had been demonstrated in clinical trials. Following completion of successful trials in low-income settings, the World Health Organization (WHO) recommended rotavirus vaccination for all infants globally in 2009. In 2018, 2 new rotavirus vaccines, Rotasiil and Rotavac, were prequalified by WHO, expanding global availability. As of March 2021, rotavirus vaccines have been introduced nationally in 106 countries. Since, Rotavirus vaccines have demonstrated effectiveness against severe disease and mortality, even among age groups in eligible for vaccination. Cross-genotypic protection has been demonstrated, and the favorable benefit-risk profile of these vaccines continues to be confirmed. Ongoing research seeks to better understand reasons for the geographic disparities in effectiveness observed, in order to optimize vaccine strategies worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.